Uncertainty surrounding President Donald Trump’s import tariffs have been “cataclysmic” for the U.S. biotech industry, but the dust will eventually settle and the sector will emerge stronger and better positioned to compete on a global scale, speakers at Thursday’s Life Sciences Future SW conference said.
The daylong conference, sponsored by Life Sciences PA, of King of Prussia, and the Pittsburgh Life Sciences Alliance, in Oakland, featured Aiken Hackett, senior vice president, federal government relations at the Biotechnology Innovation Organization, and Clayton Hall, executive vice president, government affairs at the Medical Device Manufacturers Association, both based in Washington, D.C. The event, which was held at the Wyndham Hotel, Downtown, comes as the federal government has been cutting research funding to institutions of higher learning, which have been economic generators in Pittsburgh and elsewhere.
“That was cataclysmic for the biotech industry,” Mr. Hall said about the tariffs unveiled April 2 by Trump. “It’s so difficult to do business in that kind of environment.”
The tariffs were made worse by shifting administration policies and pauses in the duties, he said.
But over time, pressure will grow to shrink or eliminate the tariffs, he added.
“If this doesn’t get fixed, you’re going to see some cracks among Republicans,” who control the U.S. House and U.S. Senate, he said.
Read More
Among Mr. Trump’s goals for the tariffs was to restore domestic manufacturing, which was driven offshore over the past 40 years by high labor costs. But Mr. Hall said bringing drug manufacturing back to the U.S. would not be easy.
“The supply chain gets exponentially complex with the complexity of the machines,” he said.
Tariffs have been the number one concern among members of the Biotechnology Innovation Organization, Ms. Hackett said. Of special concern were the discussions underway in Washington to impose import tariffs on pharmaceutical products, which have been subject to few if any import duties in the past.
Two popular federal programs that help small businesses are scheduled to expire in September, but Ms. Hackett predicted that each one would survive. The statutory authority for the Small Business Innovation Research and Small Business Technology Transfer programs expire Sept. 30 without reauthorization by Congress.
“Everyone has just focused on the next executive order coming out of the White House,” she said. “But we have an opportunity to get things done.”
Boston Globe Media’s STAT reported that National Institutes of Health grants were down $2.3 billion since Mr. Trump took office, and South Oakland-based Noveome Biotherapeutics President Eric Keller worried about foreign countries poaching U.S. scientists because of the federal government’s attack on universities.
Heidi L. Wagner, senior vice president, general manager, Cell & Gene Therapy at ElevateBio, worried about the public perception fallout from the federal government’s attacks on institutions of higher learning.
Waltham, Mass.-based ElevateBio has partnered with the University of Pittsburgh in developing a biotech lab in Hazelwood that is scheduled to open by early 2027.
“There does appear to be an assault on science and that’s unfortunate,” Ms. Wagner said. “I just hope the rhetoric in Washington doesn’t erode the public trust in science.
“I think we’re going to emerge from this nuclear winter positively,” she added.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.